AstraZeneca signs deal with Albany Molecular to produce COVID-19 vaccine candidate
Reuters
Published Sep 03, 2020 14:54
(Reuters) - AstraZeneca Plc (L:AZN) on Thursday signed a manufacturing deal with privately held Albany Molecular Research Inc to produce millions of doses of the British drugmaker's experimental coronavirus vaccine annually.
The contract drug manufacturer and research company said the agreeement will help bolster supply of the vaccine through sterile finishing services at its manufacturing plant in Albuquerque, New Mexico.
Albany Molecuar did not disclose the terms of the deal, while AstraZeneca did not immediately respond to a request for comment.
AstraZeneca has been scaling up production of the vaccine candidate, mainly through deals such as its expanded agreement with cell therapy firm Oxford Biomedica (L:OXB) to mass-produce its COVID-19 vaccine candidate.
Albany Molecular in 2017 agreed to be taken private by buyout firms Carlyle Group (O:CG) and GTCR LLC for about $922 million in cash.
Get The App
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.